513 related articles for article (PubMed ID: 30644768)
1. Patisiran for the treatment of hereditary transthyretin-mediated amyloidosis.
Yang J
Expert Rev Clin Pharmacol; 2019 Feb; 12(2):95-99. PubMed ID: 30644768
[TBL] [Abstract][Full Text] [Related]
2. Leading RNA Interference Therapeutics Part 1: Silencing Hereditary Transthyretin Amyloidosis, with a Focus on Patisiran.
Titze-de-Almeida SS; Brandão PRP; Faber I; Titze-de-Almeida R
Mol Diagn Ther; 2020 Feb; 24(1):49-59. PubMed ID: 31701435
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study.
Adams D; Polydefkis M; González-Duarte A; Wixner J; Kristen AV; Schmidt HH; Berk JL; Losada López IA; Dispenzieri A; Quan D; Conceição IM; Slama MS; Gillmore JD; Kyriakides T; Ajroud-Driss S; Waddington-Cruz M; Mezei MM; Planté-Bordeneuve V; Attarian S; Mauricio E; Brannagan TH; Ueda M; Aldinc E; Wang JJ; White MT; Vest J; Berber E; Sweetser MT; Coelho T;
Lancet Neurol; 2021 Jan; 20(1):49-59. PubMed ID: 33212063
[TBL] [Abstract][Full Text] [Related]
4. Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis.
Kristen AV; Ajroud-Driss S; Conceição I; Gorevic P; Kyriakides T; Obici L
Neurodegener Dis Manag; 2019 Feb; 9(1):5-23. PubMed ID: 30480471
[TBL] [Abstract][Full Text] [Related]
5. Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure-Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin-Mediated (hATTR) Amyloidosis.
Zhang X; Goel V; Attarwala H; Sweetser MT; Clausen VA; Robbie GJ
J Clin Pharmacol; 2020 Jan; 60(1):37-49. PubMed ID: 31322739
[TBL] [Abstract][Full Text] [Related]
6. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.
Adams D; Gonzalez-Duarte A; O'Riordan WD; Yang CC; Ueda M; Kristen AV; Tournev I; Schmidt HH; Coelho T; Berk JL; Lin KP; Vita G; Attarian S; Planté-Bordeneuve V; Mezei MM; Campistol JM; Buades J; Brannagan TH; Kim BJ; Oh J; Parman Y; Sekijima Y; Hawkins PN; Solomon SD; Polydefkis M; Dyck PJ; Gandhi PJ; Goyal S; Chen J; Strahs AL; Nochur SV; Sweetser MT; Garg PP; Vaishnaw AK; Gollob JA; Suhr OB
N Engl J Med; 2018 Jul; 379(1):11-21. PubMed ID: 29972753
[TBL] [Abstract][Full Text] [Related]
7. Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis.
Solomon SD; Adams D; Kristen A; Grogan M; González-Duarte A; Maurer MS; Merlini G; Damy T; Slama MS; Brannagan TH; Dispenzieri A; Berk JL; Shah AM; Garg P; Vaishnaw A; Karsten V; Chen J; Gollob J; Vest J; Suhr O
Circulation; 2019 Jan; 139(4):431-443. PubMed ID: 30586695
[TBL] [Abstract][Full Text] [Related]
8. Population Pharmacokinetic-Pharmacodynamic Model of Serum Transthyretin Following Patisiran Administration.
Goel V; Gosselin NH; Jomphe C; Zhang X; Marier JF; Robbie GJ
Nucleic Acid Ther; 2020 Jun; 30(3):143-152. PubMed ID: 32175804
[TBL] [Abstract][Full Text] [Related]
9. Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis.
Obici L; Berk JL; González-Duarte A; Coelho T; Gillmore J; Schmidt HH; Schilling M; Yamashita T; Labeyrie C; Brannagan TH; Ajroud-Driss S; Gorevic P; Kristen AV; Franklin J; Chen J; Sweetser MT; Wang JJ; Adams D
Amyloid; 2020 Sep; 27(3):153-162. PubMed ID: 32131641
[No Abstract] [Full Text] [Related]
10. An evaluation of patisiran: a viable treatment option for transthyretin-related hereditary amyloidosis.
Milani P; Mussinelli R; Perlini S; Palladini G; Obici L
Expert Opin Pharmacother; 2019 Dec; 20(18):2223-2228. PubMed ID: 31566422
[No Abstract] [Full Text] [Related]
11. Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis.
Butler JS; Chan A; Costelha S; Fishman S; Willoughby JL; Borland TD; Milstein S; Foster DJ; Gonçalves P; Chen Q; Qin J; Bettencourt BR; Sah DW; Alvarez R; Rajeev KG; Manoharan M; Fitzgerald K; Meyers RE; Nochur SV; Saraiva MJ; Zimmermann TS
Amyloid; 2016 Jun; 23(2):109-18. PubMed ID: 27033334
[TBL] [Abstract][Full Text] [Related]
12. APOE polymorphism in ATTR amyloidosis patients treated with lipid nanoparticle siRNA.
Niemietz C; Nadzemova O; Zibert A; Schmidt HH
Amyloid; 2020 Mar; 27(1):45-51. PubMed ID: 31648569
[TBL] [Abstract][Full Text] [Related]
13. A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis.
Coelho T; Adams D; Conceição I; Waddington-Cruz M; Schmidt HH; Buades J; Campistol J; Berk JL; Polydefkis M; Wang JJ; Chen J; Sweetser MT; Gollob J; Suhr OB
Orphanet J Rare Dis; 2020 Jul; 15(1):179. PubMed ID: 32641071
[TBL] [Abstract][Full Text] [Related]
14. [Gene therapy options for hereditary transthyretin-related amyloidosis].
Schilling M
Nervenarzt; 2022 Jun; 93(6):557-565. PubMed ID: 35419654
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and Pharmacodynamics of Patisiran in Patients with hATTR Amyloidosis and with Polyneuropathy After Liver Transplantation.
Badri P; Habtemariam B; Melch M; Clausen VA; Arum S; Li X; Jay PY; Vest J; Robbie GJ
Clin Pharmacokinet; 2023 Oct; 62(10):1509-1522. PubMed ID: 37639169
[TBL] [Abstract][Full Text] [Related]
16. Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis.
Gertz MA; Scheinberg M; Waddington-Cruz M; Heitner SB; Karam C; Drachman B; Khella S; Whelan C; Obici L
Expert Rev Clin Pharmacol; 2019 Aug; 12(8):701-711. PubMed ID: 31268366
[No Abstract] [Full Text] [Related]
17. Response by Solomon to Letter Regarding Article, "Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis: Analysis of the APOLLO Study".
Solomon SD
Circulation; 2019 Jul; 140(2):e92-e93. PubMed ID: 31283371
[No Abstract] [Full Text] [Related]
18. Letter by González-Costello et al Regarding Article, "Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-mediated Amyloidosis: Analysis of the APOLLO Study".
González-Costello J; Casasnovas C; Díez-López C
Circulation; 2019 Jul; 140(2):e90-e91. PubMed ID: 31283374
[No Abstract] [Full Text] [Related]
19. Safety and efficacy of RNAi therapy for transthyretin amyloidosis.
Coelho T; Adams D; Silva A; Lozeron P; Hawkins PN; Mant T; Perez J; Chiesa J; Warrington S; Tranter E; Munisamy M; Falzone R; Harrop J; Cehelsky J; Bettencourt BR; Geissler M; Butler JS; Sehgal A; Meyers RE; Chen Q; Borland T; Hutabarat RM; Clausen VA; Alvarez R; Fitzgerald K; Gamba-Vitalo C; Nochur SV; Vaishnaw AK; Sah DW; Gollob JA; Suhr OB
N Engl J Med; 2013 Aug; 369(9):819-29. PubMed ID: 23984729
[TBL] [Abstract][Full Text] [Related]
20. Association of Patisiran, an RNA Interference Therapeutic, With Regional Left Ventricular Myocardial Strain in Hereditary Transthyretin Amyloidosis: The APOLLO Study.
Minamisawa M; Claggett B; Adams D; Kristen AV; Merlini G; Slama MS; Dispenzieri A; Shah AM; Falk RH; Karsten V; Sweetser MT; Chen J; Riese R; Vest J; Solomon SD
JAMA Cardiol; 2019 May; 4(5):466-472. PubMed ID: 30878017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
